Forbion related stories
All articles and analysis
Forbion Capital invests in Sanifit's $41 mln roundSanifit raised 36.6 million Euros (US$41 million) in a Series C round of financing. Forbion Capital Partners took part in the round as well as Ysios Capital, Lundbeckfond Ventures, Gilde Healthcare, Edmond de Rothschild Investment Partners, “la Caixa” and Baxter Healthcare. Existing shareholders also supported the series C round. Sanifit is a Spanish clinical-stage biopharmaceutical company.
- Fonds de solidarité FTQ invest $11.5 mln in Forbion Capital
The Fonds de solidarité FTQ is investing €10.5 million (US$11.5 million) in Forbion Capital Partners' third fund. Forbion, of Naarden, the Netherlands, is a dedicated Life Sciences venture capital firm.
Fonds de solidarité FTQ commits $14.3 mln to Dutch life sciences fundThe Fonds de solidarité FTQ has made a $14.3 million commitment to the third fund of Forbion Capital Partners, a Dutch venture capital firm that invests in life sciences and biomedical technology sectors. The investment completes a recent cycle of fund commitments by the Fonds, which includes its participation in January's $134 million initial close /canada/2015/01/15/cti-life-sciences-raises-134-mln-in-first-close-of-fund-ii-boosts-staff/ of CTI Life Sciences' second fund. In the years ahead, the Fonds said it will shift its market focus to direct investments in life sciences companies. In the first quarter of 2015, the Fonds was one of the backers of new financings of enGene /canada/2015/01/26/intestinal-gene-delivery-platform-egene-nets-13-5-mln-in-series-b-round/ , an intestinal gene delivery platform, and of Thrasos Therapeutics /canada/2015/03/31/bdc-capital-and-sr-one-leads-series-d-round-for-thrasos/ , a biotherapeutics company.
- Autonomic Technologies raises $38 mln
Autonomic Technologies Inc. said Tuesday it raised $38 million in a series D round of financing led by led by Edmond de Rothschild Investment Partners, syndicated with Forbion Capital Partners. Existing investors Kleiner Perkins Caufield and Byers, InterWest Partners, Novartis Venture Fund, Aberdare Ventures and the Cleveland Clinic also participated. San Francisco-based Autonomic Technologies is a medical device company that is developing Pulsante, a microstimulator to treat severe headaches.
- Rigontec GmbH raises $5.3 mln in Series A
Rigontec GmbH said Tuesday it raised 4.8 million Euros (about US$5.3 mln) in a second closing of a series A round from Forbion Capital Partners and Sunstone Capital. Rigontec said total Series A funding was 14.25 million Euros (US$15.7 mln). Bonn, Germany-based Rigontech is a biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases.
Intestinal gene delivery platform enGene nets $13.5 mln in Series BMontréal-based enGene Inc has raised $13.5 million in Series B financing. The round was backed by an international venture capital syndicate led by Dutch firm Forbion Capital Partners and joined by Québec's Fonds de solidarité FTQ and Russian investor group Pharmstandard International S.A. Existing investor Merck Lumira Biosciences Fund, which is managed by Lumira Capital, also participated in the deal, which brings enGene's total financing to date to over $30 million. The company, which develops novel DNA-based therapeutics, said that it will use the new funds to advance its platform technology for delivering genes to cells lining the gastrointestinal tract.
Knight Therapeutics commits $35 mln to Domain, Sanderling fundsCanadian specialty pharmaceutical company Knight Therapeutics Inc (TSX: GUD) has committed a total of US$35 million to new funds managed by U.S. life sciences venture capital firms Domain Associates and Sanderling Ventures. The fund commitments, which follow the company's $30 million commitment in October /canada/2014/10/28/knight-therapeutics-invests-30-mln-in-teralys-capital-life-sciences-fund/ to Teralys Capital Innovation Fund LP, a life sciences fund managed by Canadian fund of funds manager Teralys Capital, reflect Knight Therapeutics' continuing product sourcing strategy.
- Forbion Capital sells PneumRx
Forbion Capital Partners has sold PneumRx to BTG. Cash consideration was $230 million and up to $245 million in performance related future milestone payments.PneumRx is a interventional pulmonology business that makes and distributes the RePneu Coil System, which aims to treat advanced emphysema.
Knight Therapeutics invests $30 mln in Teralys Capital life sciences fundKnight Therapeutics Inc (TSX: GUD), a specialty pharmaceutical company, has committed $30 million to Teralys Capital Innovation Fund LP, a life sciences fund managed by Canadian fund of funds manager Teralys Capital. The initiative follows the company's investments in other fund vehicles, including its commitment /canada/2014/10/03/knight-therapeutics-to-commit-27-mln-to-dutch-vc-fund/ earlier this month to Dutch venture capital firm Forbion Capital Partners. The Montréal-based Knight Therapeutics said it plans to invest up to $130 million in its fund strategy, which is intended to secure Canadian product rights for the company. Teralys manages a $600 million fund sponsored by the Caisse de dépôt et placement du Québec, Fonds de solidarité FTQ and Investissement Québec.
Knight Therapeutics to commit $27 mln to Dutch VC fundCanadian specialty pharmaceutical company Knight Therapeutics Inc (TSX: GUD) has agreed to commit EUR 19.5 million ($27.5 million) to the third life sciences fund managed by Dutch venture capital firm Forbion Capital Partners. The commitment, which follows an earlier commitment to a life sciences fund managed by Sectoral Asset Management, expands Knight's product sourcing strategy for the Canadian market, the company said. Knight plans to commit up to $130 million to this strategy. Forbion this month announced a first close http://www.forbion.com/#/news/forbion-capital-partners-announces-first-close-of-fcf-iii of Forbion Capital Fund III CV at EUR 92 million ($129.6 million).